The financials
ResMed by the numbers
ResMed (RMD) reported revenue of $1.43B in Q3 2026 (quarter ended March 31, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 62% and net income of $399M (28% of revenue). For the full year FY2025, revenue was $5.15B (+9.8% year on year) and net income $1.40B. Its largest product in 2026-Q1 was Sleep And Breathing Health at $1.26B, 88% of the disclosed total, just ahead of Residential Care Software at 12%.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $1.43B | $1.29B | +11% |
| Gross profit | $891M | $766M | +16% |
| Operating income | $500M | $426M | +17% |
| Net income | $399M | $365M | +9.2% |
| Diluted EPS | $2.74 | $2.48 | +10% |
| Product | Revenue | Share |
|---|---|---|
| Sleep And Breathing Health | $1.26B | 88% |
| Residential Care Software | $171M | 12% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $1.43B (+0.60%)
Sleep And Breathing Health grew +11% year on yearResidential Care Software +6.0% year on year
Segment Latestquarter on quarteryear on year
- Sleep And Breathing Health$1.26B$1.26BQoQ +0.36%year on year +11%+0.36%+11%
- Residential Care Software$170.9M$170.9MQoQ +2.4%year on year +6.0%+2.4%+6.0%
Medical Instruments & Supplies
Ranks #3 of 27 by Smart Score